V600E inhibitors is associated with reactivation of mitogen-activated protein kinase (MAPK) signaling at different levels in melanoma. To identify downstream effectors of MAPK signaling that could be used as potential additional therapeutic targets for BRAF V600E inhibitors, we used hTERT/CDK4R24C/p53DD-immortalized primary human melanocytes genetically modified to ectopically express BRAFV600E or NRASG12D and observed induction of the AP-1 transcription factor family member c-Jun. Using a dominant negative approach, in vitro cell proliferation assays, western blots, and flow cytometry showed that MAPK signaling via BRAF V600E promotes melanoma cell proliferation at G1 through AP-1-mediated negative regulation of the INK4 family member, cyclin-dependent kinase inhibitor 2C (CDKN2C), and the CIP/KIP family member, cyclin-dependent kinase inhibitor 1A (CDKN1A). These effects were antagonized by pharmacological inhibition of CDKN2C and CDKN1A targets CDK2 and CDK4 in vitro. In contrast to BRAFV600E or NRASG12D-expressing melanocytes, melanoma cells have an inherent resistance to suppression of AP-1 activity by BRAF V600E -or MEK-inhibitors. Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF V600E -or MEK-inhibitors on melanoma cell viability in vitro and growth in athymic nude Foxn1 nu mice (P = .03 when mean tumor volume at day 13 was compared for BRAF V600E inhibitor vs BRAF V600E inhibitor plus CDK2/4 inhibition; P = .02 when mean tumor volume was compared for MEK inhibitor vs MEK inhibitor plus CDK2/4 inhibition; P values were calculated by a two-sided Welch t test; n = 4-8 mice per group).
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Melanoma responses to BRAF V600E inhibition (1,2) are often followed by disease recurrence through reactivation of the mitogen-activated protein kinase (MAPK) pathway (3), a nonlinear dynamic regulatory network of protein kinases (4) . Resistance to BRAF V600E inhibition occurs at different levels of this network, eg, through acquisition of new activating mechanisms such as mutations in NRAS or MEK (5, 6) , MEK kinase activation and CRAF overexpression (7), activation of alternative wild-type RAF heterodimers (8) , or activation of platelet-derived growth factor receptor β (5) and insulin-like growth factor 1 receptor via functional cross-talk (8) . Thus, we hypothesized that inhibition of downstream effectors of MAPK signaling could be a potential therapeutic strategy for BRAF V600E inhibitor-resistant melanomas. To our knowledge, this therapeutic strategy has not been explored for melanoma.
To identify downstream effectors of MAPK signaling that could be used as potential therapeutic targets, we used hTERT/ CDK4R24C/p53DD-immortalized primary human melanocytes genetically modified to ectopically express BRAF V600E or NRAS G12D (9) . Protein lysates were subjected to western blot for activated and total c-Jun, an oncogenic subunit of the AP-1 transcription factor (Supplementary Methods, available online). AP-1 is a homo/heterodimeric transcription factor composed of c-Jun and JunD homo-or hetero dimers, or heterodimers with other basic leucine-zipper family members (10), and is a major transducer of cellular proproliferative signals (10, 11) . We found that ectopic expression of BRAF V600E or NRAS G12D increased activation of c-Jun relative to parental hTERT/ CDK4R24C/p53DD cells (Figure 1, A) . Furthermore, when the cells were treated with the MEK1/2 inhibitor PD98059 (12) (Selleck Chemicals, Houston, TX), AP-1 activity was markedly decreased compared with untreated and solvent (control)-treated cells as detected by an AP-1-secreted alkaline phosphatase reporter gene assay (Supplementary Methods, available online).
To determine the effect of c-Jun knockdown on MAPK signaling in human melanoma cells, LOXIMVI cells were transiently transfected with three different small interfering RNAs (siRNAs) targeting c-Jun (Supplementary Methods, available online). After 48 hours, c-Jun knockdown was confirmed by western blot, and siRNA #145018 was used for all subsequent experiments (data not shown). siRNA transfected-LOXIMVI cells had decreased AP-1 activity relative to cells transfected with a nontarget control siRNA (mean AP-1 activity = 65.2%, SD = 18.4% vs 100%, SD = 7.0%, two-sided P = .07) (Supplementary Figure 1 Consistent with these findings, transfection of LOXIMVI cells with siRNA targeting CDKN2C or CDKN1A in vitro partially rescued dn-AP1-induced suppression of cell proliferation, and when both CDKN2C and CDKN1A siRNAs were cotransfected into LOXIMVI cells, cell proliferation (as measured by counting cell numbers over time, which is shown in Figure 1 (15), an important prerequisite for cell transformation, was described. Furthermore, mutations in CDK4 have been described in melanoma-prone families and patients with multiple primary melanomas (16), CDK4 amplification has been previously reported in subtypes of sporadic melanoma (17) , and reduced CDKN1A expression has been implicated in melanoma metastasis (18) .
As AP-1 is a transcription factor, we performed cotransfection assays with wild-type CDKN2C and CDKN1A promoter-luciferase reporter plasmids (19, 20) (Figure 1, H) . These results indicate that CDKN2C is a direct target of AP-1.
In addition, we assessed the relationship between c-Jun expression and that of CDKN2C and CDKN1A using RNA and tissues obtained from 30 melanoma patients. The primary human melanomas were assigned to two groups (low and high) based on low vs high expression of CDKN2C and CDKN1A (mean relative CDKN2C mRNA expression = 0.5, SD = 0.3 vs 2.5, SD = 1.8, respectively, two-sided P = .007; mean relative CDKN1A mRNA expression = 0.9, SD = 0.4 vs 3.0, SD = 1.2, respectively, two-sided P < .001; n = 8 and 11, respectively) as determined by quantitative real-time PCR of available RNA (Supplementary Methods, available online). Nuclear phospho-c-Jun expression in the corresponding tissues was then analyzed by immunohistochemistry (Supplementary Methods, available online), and the percentage of cells with 0-1+, 2+, and 3+ staining was determined. A table summarizing the data and representative stained tissues are depicted in Supplementary Figure 2 , B (available online). High levels of CDKN2C and CDKN1A mRNA were associated with low phospho-c-Jun staining (0-1+), whereas low levels of CDKN2C and CDKN1A mRNA were associated with high phosphoc-Jun staining (2+ and 3+). These results further substantiate the role of AP-1 in the negative regulation of CDKN2C and CDKN1A transcription. In accordance with these results, previous studies in animal models have shown that CDK4 R24C and a CDKN2C deficiency increase melanoma susceptibility, but additional MAPK signaling is required for melanomas to develop (22, 23) .
Because the expression of CDKN2C and CDKN1A targets, ie, CDK2 and CDK4/6, was unaffected by dnAP-1 (Supplementary Figure 1 , F, available online) and is rarely lost in human melanoma (24), our results provide rationale for the development of novel combination therapeutic strategies for melanoma. In contrast to single agent-treatment with inhibitors at doses selective to CDK2 or CDK4 inhibition [NU6140 (25) , CVT-313 (26), NSC625987 (27) , indolocarbazole CDK4-I (28) online), and CDK2/4 inhibition augmented statistically significant growth reduction of melanoma xenografts in vivo by the BRAF and MEK inhibitors (P = .03 when mean tumor volume at day 13 was compared for GDC-0879 vs GDC-0879 plus CDK2/4 inhibition; P = .02 when mean tumor volume was compared for PD184352/CI1040 vs PD184352/CI1040 plus CDK2/4 inhibition; n = 4-8 mice per group) (mean tumor volume at day 13: GDC-0879 = 0. Our study was not without limitations. The restricted ability of cell-based studies to predict clinical behavior is an inherent restraint. Also, the varied response to cyclin-dependent kinase inhibitors between different melanoma cell lines is unexplained at this time. The small number of available human tissue samples used in our study also limits the interpretation of our results.
Nevertheless, our data show a statistically significant augmentation of BRAF V600E -and MEK-inhibitors by CDK2/4 inhibition in vivo. Our findings provide rationale and support for further clinical exploration of this novel combination therapeutic strategy for melanoma. 
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